Merck to register, lower cost of antiretroviral Atripla in developing countries

Pharmaceutical company Merck on Friday said that it will begin registering the antiretroviral drug Atripla in developing countries and that it will lower the cost of the drug in countries with high HIV prevalence, the Bergen Record reports.

According to the Record, Merck announced that through the first half of 2007, Atripla will be registered in 45 countries in the Middle East and Africa and in nine countries in Latin America, the Caribbean and Asia.

Registration of the drug began in November 2006 in Ethiopia, according to a Merck statement.

The company also announced that Atripla will be priced on a sliding scale based on each country's wealth.

The drug will cost $1.68 per tablet in countries with an HIV prevalence of more than 1%, and it will cost $2.83 per tablet in the 22 wealthier countries that have a lower HIV prevalence, according to the Record.

Atripla, which was approved by FDA in July 2006, combines Bristol-Myers Squibb's Sustiva and Gilead's Truvada into a single pill.

Merck and Gilead in August 2006 agreed to partner to make the drug more widely available in developing countries.

Under the partnership, Merck will handle distribution of Atripla, and Gilead will deal with manufacturing (Prial, Bergen Record, 2/17).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Promising new approach to combat HIV